RecruitingNCT06864195

A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions

Development of a Breath Test Using Volatile Organic Markers for Monitoring Cirrhosis and Detecting Primary Liver Tumours (VOCAL2)


Sponsor

Imperial College London

Enrollment

750 participants

Start Date

Feb 13, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis. The test analyzes tiny chemicals in exhaled breath called volatile organic compounds (VOCs) to identify signs of liver disease. Who can take part? Adults aged 18 or older who: Have liver cancer (hepatocellular carcinoma or cholangiocarcinoma), or Have liver cirrhosis or primary sclerosing cholangitis, or Have tummy symptoms but a normal liver scan. What's involved? Participants will: Give a breath sample after fasting for 6 hours. Answer a few health questions. Allow access to relevant medical records. The appointment lasts about 1 hour at an NHS hospital. Benefits \& Risks This research could lead to an earlier, easier way to detect liver cancer, but there's no direct health benefit for participants. There are no risks, as breath sampling is completely non-invasive and safe. Where is the study happening? Led by Imperial College London, running in NHS hospitals across the UK. Who is funding the study? The study is funded by Rosetrees and Stoneygate Trust. Contact Information Email: vocal-study@imperial.ac.uk Phone: +44 (0)20 7594 3396


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a simple breath test to see if it can detect liver cancer or tell the difference between liver cancer and other liver conditions like cirrhosis or primary sclerosing cholangitis (PSC). **You may be eligible if...** - You are 18 or older - You have confirmed liver cancer (hepatocellular carcinoma or cholangiocarcinoma) - OR you have cirrhosis (scarring of the liver), primary sclerosing cholangitis, or non-specific stomach symptoms with a normal liver (comparison groups) **You may NOT be eligible if...** - You have an active infection or have been on immunosuppressive medications within the past 8 weeks - You have a history of certain conditions that may affect the test results (as assessed by the study team) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Imperial College London

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06864195


Related Trials